Author/Authors :
Nathan J. Moerke، نويسنده , , Huseyin Aktas، نويسنده , , Han Chen، نويسنده , , Sonia Cantel، نويسنده , , Mikhail Y. Reibarkh، نويسنده , , Amr Fahmy، نويسنده , , John D. Gross، نويسنده , , Alexei Degterev، نويسنده , , Junying Yuan، نويسنده , , Michael Chorev، نويسنده , , Jose A. Halperin، نويسنده , , Gerhard Wagner، نويسنده ,
Abstract :
Assembly of the eIF4E/eIF4G complex has a central role in the regulation of gene expression at the level of translation initiation. This complex is regulated by the 4E-BPs, which compete with eIF4G for binding to eIF4E and which have tumor-suppressor activity. To pharmacologically mimic 4E-BP function we developed a high-throughput screening assay for identifying small-molecule inhibitors of the eIF4E/eIF4G interaction. The most potent compound identified, 4EGI-1, binds eIF4E, disrupts eIF4E/eIF4G association, and inhibits cap-dependent translation but not initiation factor-independent translation. While 4EGI-1 displaces eIF4G from eIF4E, it effectively enhances 4E-BP1 association both in vitro and in cells. 4EGI-1 inhibits cellular expression of oncogenic proteins encoded by weak mRNAs, exhibits activity against multiple cancer cell lines, and appears to have a preferential effect on transformed versus nontransformed cells. The identification of this compound provides a new tool for studying translational control and establishes a possible new strategy for cancer therapy.